



PATENT
Attorney Docket No. 110.01270101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): James B. McCarthy et al.)	Group Art Unit:	1642
)		
Serial No.: 09/937,076)	Examiner:	unknown
Confirmation No.: 4527)		
)		
Filed: September 19, 2001)		
International Filing Date: March 22, 2000)		

For: METHODS OF USE OF β 1-INTEGRIN INHIBITORS

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application.

Consideration of each of the documents listed on the attached 1449 forms is respectfully requested. Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 forms, marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

The Examiner's attention is directed to the following additional information. Claims 13-24, which are directed toward methods for treating burn-type injuries, claim priority to U.S. Provisional Application Serial No. 60/125,634 filed March 22, 1999 in the names of William J. Mileski and Gordon A. Jamieson. William J. Mileski was under an obligation to assign his rights to The University of Texas System. Certain of the other claims claim priority to U.S. Provisional Application Serial No. 60/167,528 filed November 24, 1999 in the name of Gordon A. Jamieson.

Information Disclosure Statement

Page 2

Applicant(s): James B. McCarthy et al.
Serial No.: 09/937,076 Confirmation No.: 4527
Filed: September 19, 2001
International Filing Date: March 22, 2000
For: METHODS OF USE OF β 1-INTEGRIN INHIBITORS

Applicants also wish to bring the Examiner's attention to the following pending U.S. Application, as well as any prior art and any provisional U.S. patent applications referenced therein. A copy of the below-listed pending U.S. Patent Application is provided herewith.

List of Pending Non-Published U.S. Patent Applications

Applicants	Application Number	Filing Date	Serial No. of Provisional Application to which listed Application claims priority
James B. McCarthy et al.	09/600,432	10/02/00	60/125,634 60/167,538

It is believed that no fee is due, as this Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 13-4895. The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this paper is being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on this 11 day of March, 2002.

Ann M. Mueting
Ann M. Mueting

Respectfully submitted for
JAMES B. McCARTHY ET AL.
By
Mueting, Raasch & Gebhardt, P.A.
P.O. Box 581415
Minneapolis, MN 55458-1415
Phone: (612)305-1220
Facsimile: (612)305-1228
Customer Number 26813



26813

PATENT TRADEMARK OFFICE

March 11, 2002
Date

By:

Ann M. Mueting
Ann M. Mueting
Reg. No. 33,977
Direct Dial (612)305-1217



PATENT
Attorney Docket No. 110.01270101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): James B. McCarthy et al.)	Group Art Unit:	1642
)		
Serial No.: 09/937,076)	Examiner:	unknown
Confirmation No.: 4527)		
)		
Filed: September 19, 2001)		
International Filing Date: March 22, 2000)		

For: METHODS OF USE OF β 1-INTEGRIN INHIBITORS

**DOCUMENTS ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT
FILED MARCH 11, 2002**

PART 1 OF 4



PATENT
Attorney Docket No. 110.01270101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): James B. McCarthy et al.)	Group Art Unit:	1642
)		
Serial No.: 09/937,076)	Examiner:	unknown
Confirmation No.: 4527)		
)		
Filed: September 19, 2001)		
International Filing Date: March 22, 2000)		
For:			
METHODS OF USE OF β 1-INTEGRIN INHIBITORS			

**DOCUMENTS ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT
FILED MARCH 11, 2002**

PART 2 OF 4



PATENT
Attorney Docket No. 110.01270101


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): James B. McCarthy et al.)	Group Art Unit:	1642
)		
Serial No.: 09/937,076)	Examiner:	unknown
Confirmation No.: 4527)		
)		
Filed: September 19, 2001)		
International Filing Date: March 22, 2000)		

For: METHODS OF USE OF β 1-INTEGRIN INHIBITORS

**DOCUMENTS ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT
FILED MARCH 11, 2002**

PART 3 OF 4



PATENT
Attorney Docket No. 110.01270101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): James B. McCarthy et al.)	Group Art Unit:	1642
)		
Serial No.: 09/937,076)	Examiner:	unknown
Confirmation No.: 4527)		
)		
Filed: September 19, 2001)		
International Filing Date: March 22, 2000)		

For: METHODS OF USE OF β 1-INTEGRIN INHIBITORS

**DOCUMENTS ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT
FILED MARCH 11, 2002**

PART 4 OF 4

**INFORMATION
DISCLOSURE
STATEMENT**

Atty. Docket No.: 110.01270101


Serial No.: 09/937,076

Applicant(s): McCarthy et al.

Confirmation No.: 4527

Filing Date: September 19, 2001

Group: 1642

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	4,839,464	06/13/89	McCarthy et al.			
	4,938,949	07/03/90	Borch et al.			
	5,019,646	05/28/91	Furcht et al.			
	5,116,368	05/26/92	McCarthy et al.			
	5,147,797	09/15/92	McCarthy et al.			
	5,171,271	12/15/92	Furcht et al.			
	5,278,063	01/11/94	Hubbell et al.			
	5,294,551	03/15/94	Furcht et al.			
	5,330,911	07/19/94	Hubbell et al.			
	5,380,668	01/10/95	Herron			
	5,382,569	01/17/95	Cody et al.			
	5,545,620	08/13/96	Wahl et al.			
	5,591,719	01/07/97	Furcht et al.			
	5,595,887	01/21/97	Coolidge et al.			
	5,710,123	01/20/98	Heavner et al.			
	5,731,409	03/24/98	Fields et al.			
	5,744,515	04/28/98	Clapper			
	5,840,691	11/24/98	Furcht et al.			
	5,846,536	12/08/98	Bissell et al.			
	5,853,744	12/29/98	Mooradian et al.			
	6,013,628	01/11/00	Skubitz et al.			

EXAMINER**Date Considered**

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION
DISCLOSURE
STATEMENT**

Atty. Docket No.: 110.01270101

Serial No.: 09/937,076

Applicant(s): McCarthy et al.

Confirmation No.: 4527

Filing Date: September 19, 2001

Group: 1642

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	EP 347 890 A1	12/27/89	Europe				
	EP 347 890 B1	12/27/89	Europe				
	EP 576 898 A2	01/05/94	Europe				
	EP 576 898 A3	01/05/94	Europe				
	JP 6016568 A	01/25/94	Japan (with English language abstract)				X
	WO 89/01942 A1	03/09/89	PCT				
	WO 93/17047 A1	09/02/93	PCT				
	WO 94/17097 A1	08/04/94	PCT				
	WO 97/23451 A1	07/03/97	PCT (with English language abstract)				X
	WO 98/00395 A1	01/08/98	PCT (with English language abstract)				X
	WO 99/37669 A1	07/29/99	PCT				
	WO 00/56350 A2	09/28/00	PCT				
	WO 00/56350 A3	09/28/00	PCT				

OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)

Examiner Initial	Document Description
	Adelsman et al., "Stimulation of β 1-Integrin Function by Epidermal Growth Factor and Heregulin- β Has Distinct Requirements for erbB2 but a Similar Dependence on Phosphoinositide 3-OH Kinase," <u>Molecular Biology of the Cell</u> , 10(9):2861-2878 (September, 1999).
	Akiyama et al., "Fibronectin," <u>Advances in Enzymology and Related Areas of Molecular Biotechnology</u> , Vol. 59, Meister, ed., John Wiley and Sons, New York, NY; title page, publication page, and pages 1-57 (1987).

EXAMINER**Date Considered**

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION
DISCLOSURE
STATEMENT**

Atty. Docket No.: 110.01270101


Serial No.: 09/937,076

Applicant(s): McCarthy et al.

Confirmation No.: 4527

Filing Date: September 19, 2001

Group: 1642



Examiner Initials	Document Description
	American Type Culture Collection, "ATCC Number 25923," organism: <i>Staphylococcus aureus</i> ; designation: Seattle 1945 [online]; Manassas, VA [retrieved on 2002-02-06] from the Internet. Retrieved from the Internet: <URL: http://phage.atcc.org/cgi-bin/searchengine/longview.cgi?view=ba,4359370,25923&text=25923 >, 3 pages.
	Boykin et al., "In Vivo Microcirculation of a Scald Burn and the Progression of Postburn Dermal Ischemia," <u>Plastic and Reconstructive Surgery</u> , 66(2):191-198 (1980).
	Brienzo, <u>Identification of a Novel Anti-adhesion Integrin-binding Motif Within a Fibronectin Synthetic Peptide</u> , PhD Thesis, University of Minnesota; title page, table of contents, and pages 1-110 (1998).
	Bruck et al., "The Use of Synthetic Analogues of Arg-Gly-Asp (RGD) and Soluble Receptor of Tumor Necrosis Factor to Prevent Acute and Chronic Experimental Liver Injury," <u>Yale Journal of Biology and Medicine</u> , 70(4):391-402 (1997).
	Carrico et al., "Chapter 12: Transfusion, Autotransfusion, and Blood Substitutes," <u>Trauma</u> , 4 th Ed., Mattox et al., eds., McGraw-Hill Companies, New York, NY; publication page and pages 233-243 (2000).
	Chappell et al., "Inhibition of Leukocyte-Mediated Tissue Destruction by Synthetic Fibronectin Peptide (Trp-9-Tyr)," <u>Journal of Burn Care and Rehabilitation</u> , 20(6):505-510 (November, 1999); presented at 31 st Annual Meeting, American Burn Association, March 24-27, Lake Buena Vista, FL, (March 25, 1999).
	Cue et al., "A nonpeptide integrin antagonist can inhibit epithelial cell ingestion of <i>Streptococcus pyogenes</i> by blocking formation of integrin alpha 5beta 1-fibronectin-M1 protein complexes," <u>Proceedings of the National Academy of Sciences, USA</u> , 97(6):2858-63 (2000).
	Duan et al., "Enhancement of nigral graft survival in rat brain with the systemic administration of synthetic fibronectin peptide V," <u>Neuroscience</u> , 100(3):521-30 (2000).
	Fields et al., "Chapter 3: Principles and Practice of Solid-Phase Peptide Synthesis," <u>Synthetic Peptides: A User's Guide</u> , Grant, ed., W. H. Freeman & Co., New York, NY; title page, publication page, table of contents, and pages 77-183 (1992).

EXAMINER**Date Considered**

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION
DISCLOSURE
STATEMENT**

Atty. Docket No.: 110.01270101


Serial No.: 09/937,076

Applicant(s): McCarthy et al.

Confirmation No.: 4527

Filing Date: September 19, 2001

Group: 1642



Examiner Initials	Document Description
	Furcht et al., "Editorial: Tumor Cell Invasion, Matrix Metalloproteinases, and the Dogma," <u>Laboratory Investigation</u> , 70(6):781-783 (1994).
	Guan et al., "Lymphoid Cells Recognize an Alternatively Spliced Segment of Fibronectin via the Integrin Receptor $\alpha_4\beta_1$," <u>Cell</u> , 60(1):53-61 (1990).
	Guo et al., "Fibronectin Peptide (FN C/H V-Y) Assay and Stability in Human and Rat Plasma," Abstract 4029, American Association of Pharmaceutical Scientists Annual Meeting, November 14-18, New Orleans, LA (1999).
	Hallenbeck et al., "Polymorphonuclear Leukocyte Accumulation in Brain Regions with Low Blood Flow During the Early Postischemic Period," <u>Stroke</u> , 17(2):246-253 (1986).
	Hines et al., "Synthetic Fibronectin Peptides Interrupt Inflammatory Cell Infiltration in Transforming Growth Factor $\beta 1$ Knockout Mice," <u>Proceedings of the National Academy of Sciences, USA</u> , 91(11):5187-5191 (1994).
	Hogg et al., "The Sticking Point: How Integrins Bind to Their Ligands," <u>Trends in Cell Biology</u> , 4:379-382 (1994).
	Huebsch et al., "Endothelial Cell Interactions With Synthetic Peptides From the Carboxyl-Terminal Heparin-Binding Domains of Fibronectin," <u>Circulation Research</u> , 77(1):43-53 (1995).
	Huhtala et al., "Cooperative Signaling by $\alpha 5\beta 1$ and $\alpha 4\beta 1$ Integrins Regulates Metalloproteinase Gene Expression in Fibroblasts Adhering to Fibronectin," <u>The Journal of Cell Biology</u> , 129(3):867-879 (1995).
	Humphries et al., "A Synthetic Peptide from Fibronectin Inhibits Experimental Metastasis of Murine Melanoma Cells," <u>Science</u> , 233(4762):467-470 (1986).
	Humphries, "Integrin Activation: the Link Between Ligand Binding and Signal Transduction," <u>Current Opinion in Cell Biology</u> , 8(5):632-640 (1996).
	Humphries et al., "An Anthropomorphic Integrin," <u>Science</u> , 294(5541):316-7 (2001).
	Hynes, "Integrins: A Family of Cell Surface Receptors," <u>Cell</u> , 48(4):549-554 (1987).
	Iida et al., "Coordinate Role for Cell Surface Chondroitin Sulfate Proteoglycan and $\alpha 4\beta 1$ Integrin in Mediating Melanoma Cell Adhesion to Fibronectin," <u>The Journal of Cell Biology</u> , 118(2):431-444 (1992).

EXAMINER**Date Considered**

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION
DISCLOSURE
STATEMENT**

Atty. Docket No.: 110.01270101


Serial No.: 09/937,076

Applicant(s): McCarthy et al.

Confirmation No.: 4527

Filing Date: September 19, 2001

Group: 1642



Examiner Initials	Document Description
	Irie et al., "Critical Amino Acid Residues for Ligand Binding Are Clustered in a Predicted β -turn of the Third N-terminal Repeat in the Integrin $\alpha 4$ and $\alpha 5$ Subunits," <u>The EMBO Journal</u> , 14(22):5550-5556 (1995).
	Irie et al., "Multiple Loop Structures Critical for Ligand Binding of the Integrin A4 Subunit in the Upper Face of the β -propeller Mode 1," <u>Proceedings of the National Academy of Sciences USA</u> , 94(14):7198-7203 (1997).
	Isberg et al., "Multiple β_1 Chain Integrins Are Receptors for Invasin, a Protein That Promotes Bacterial Penetration into Mammalian Cells," <u>Cell</u> , 60(5):861-871 (1990).
	Jackson et al., "Potent $\alpha 4 \beta 1$ Peptide Antagonists as Potential Anti-Inflammatory Agents," <u>Journal of Medicinal Chemistry</u> , 40(21):3359-3368 (1997).
	Johnson, "8. The Cutaneous Circulation," <u>Laser-Doppler Blood Flowmetry</u> , Shepherd et al., eds., Kluwer Academic Publishers, Norwell, MA; title page, publication page, and pages 121-139 (1990).
	Kochanek et al., "Polymorphonuclear Leukocytes and Monocytes/Macrophages in the Pathogenesis of Cerebral Ischemia and Stroke," <u>Stroke</u> , 23(9):1367-1379 (1992).
	Lasky, "Selectins: Interpreters of Cell-Specific Carbohydrate Information During Inflammation," <u>Science</u> , 258(5084):964-969 (1992).
	Lasky, "How Integrins Are Activated," <u>Nature</u> , 390(6655):15, 17 (1997).
	Lasz et al., " β_3 Integrin Derived Peptide 217-230 Inhibits Fibrinogen Binding and Platelet Aggregation: Significance of RGD Sequences and Fibrinogen A α -Chain," <u>Biochemical and Biophysical Research Communications</u> , 190(1):118-124 (1993).
	Lauer et al., "Inhibition of Melanoma Cell Binding to Type IV Collagen by Analogs of Cell Adhesion Regulator," <u>Journal of Medicinal Chemistry</u> , 40(19):3077-3084 (1997).
	Lenter et al., "A Monoclonal Antibody Against an Activation Epitope on Mouse Integrin Chain β_1 Blocks Adhesion of Lymphocytes to the Endothelial Integrin $\alpha_6 \beta_1$," <u>Proceedings of the National Academy of Sciences, USA</u> , 90(19):9051-9055 (1993).
	Leong et al., "Identification of the Integrin Binding Domain of the <i>Yersinia Pseudotuberculosis</i> Invasin Protein," <u>The EMBO Journal</u> , 9(6):1979-1989 (1990).

EXAMINER

Date Considered

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION
DISCLOSURE
STATEMENT**

Atty. Docket No.: 110.01270101

Serial No.: 09/937,076

Applicant(s): McCarthy et al.

Confirmation No.: 4527

Filing Date: September 19, 2001

Group: 1642

Examiner Initials	Document Description
	Levrey et al., "Induction of Fibroblast Apoptosis by Soluble Fibronectin Peptides," Abstract 1050, 37 th Annual Meeting of the American Society for Cell Biology, December 13-17, 1997, Washington, D.C., <u>Molecular Biology of the Cell</u> , 8:181A (November, 1997).
	Lobb et al., "Small Molecule Antagonists of $\alpha 4$ Integrins: Novel Drugs for Asthma," <u>Expert Opinion on Investigational Drugs</u> , 8(7):935-945 (July, 1999).
	Loftus et al., "Integrin-mediated Cell Adhesion: The Extracellular Face," <u>The Journal of Biological Chemistry</u> , 269(41):25235-25238 (1994).
	Madden et al., "A Peptide Derived from Neutrophil Inhibitory Factor (NIF) Blocks Neutrophil Adherence to Endothelial Cells," <u>Inflammation Research</u> , 46(6):216-223 (1997).
	Matsuo et al., "Role of Neutrophils in Radical Production During Ischemia and Reperfusion of the Rat Brain: Effect of Neutrophil Depletion on Extracellular Ascorbyl Radical Formation," <u>Journal of Cerebral Blood Flow and Metabolism</u> , 15(6):941-947 (1995).
	McCarthy et al., "Laminin and Fibronectin Promote the Haptotactic Migration of B16 Mouse Melanoma Cells In Vitro," <u>The Journal of Cell Biology</u> , 98(4):1474-1480 (1984).
	McCarthy et al., "The Role of Cell Adhesion Proteins - Laminin and Fibronectin - in the Movement of Malignant and Metastatic Cells," <u>Cancer and Metastasis Reviews</u> , 4(2):125-152 (1985).
	McCarthy et al., "Human Fibronectin Contains Distinct Adhesion- and Motility-promoting Domains for Metastatic Melanoma Cells," <u>The Journal of Cell Biology</u> , 102(1):179-188 (1986).
	McCarthy et al., "Metastasis Inhibition of Different Tumor Types by Purified Laminin Fragments and a Heparin-Binding Fragment of Fibronectin," <u>Journal of the National Cancer Institute</u> , 80(2):108-116 (1988).
	McCarthy et al., "Localization and Chemical Synthesis of Fibronectin Peptides with Melanoma Adhesion and Heparin Binding Activities," <u>Biochemistry</u> , 27(4):1380-1388 (1988).
	McCarthy et al., "RGD-independent Cell Adhesion to the Carboxy-terminal Heparin-binding Fragment of Fibronectin Involves Heparin-dependent and -independent Activities," <u>The Journal of Cell Biology</u> , 110(3):777-787 (1990).

EXAMINER**Date Considered**

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION
DISCLOSURE
STATEMENT**

Atty. Docket No.: 110.01270101

Serial No.: 09/937,076

Applicant(s): McCarthy et al.

Confirmation No.: 4527

Filing Date: September 19, 2001

Group: 1642

MAR 19 2002

O I P E J C B 7
PATENT & TRADEMARK OFFICE

Examiner Initial	Document Description
	McCarthy et al., "Tumor Cell Adhesive Mechanisms and Their Relationship to Metastasis," <u>Seminars in Cancer Biology</u> , 2(3):155-167 (1991).
	McCartney-Francis et al., "Autoimmune Sjögren's-Like Lesions in Salivary Glands of TGF- β 1-Deficient Mice Are Inhibited by Adhesion-Blocking Peptides," <u>The Journal of Immunology</u> , 157(3):1306-1312 (1996).
	McCarthy et al., "Human monocyte binding to fibronectin enhances IFN-gamma-induced early signaling events," <u>The Journal of Immunology</u> , 159(5):2424-30 (1997).
	McCartney-Francis et al., "Lacrimal Gland Inflammation Is Responsible for Ocular Pathology in TGF- β 1 Null Mice," <u>American Journal of Pathology</u> , 151(5):1281-1288 (1997).
	Mileski et al., "Streptococcus Pneumoniae-Stimulated Macrophages Induce Neutrophils to Emigrate by a CD18-Independent Mechanism of Adherence," <u>Circulatory Shock</u> , 31(3):259-267 (1990).
	Mileski et al., "Inhibition of Leukocyte-Endothelial Adherence following Thermal Injury," <u>Journal of Surgical Research</u> , 52(4):334-339 (1992).
	Mileski et al., "The Accuracy of Burn Wound Assessment by Laser Doppler Flowmetry is Improved by Serial Measurements," Abstract 31, 31 st Annual Meeting, American Burn Association, March 24-27, Lake Buena Vista, FL, (March, 1999).
	Mohri, "Interaction of Fibronectin With Integrin Receptors: Evidence by Use of Synthetic Peptides," <u>Peptides</u> , 18(6):899-907 (1997).
	Mooradian et al., "Characterization of FN-C/H-V, a Novel Synthetic Peptide From Fibronectin That Promotes Rabbit Corneal Epithelial Cell Adhesion, Spreading, and Motility," <u>Investigative Ophthalmology & Visual Science</u> , 34(1):153-164 (1993).
	Moyle et al., "A Hookworm Glycoprotein That Inhibits Neutrophil Function Is a Ligand of the Integrin CD11b/CD18," <u>The Journal of Biological Chemistry</u> , 269(13):10008-10015 (1994).
	Norgard-Sumnicht et al., "Calcium-Dependent Heparin-Like Ligands for L-Selectin in Nonlymphoid Endothelial Cells," <u>Science</u> , 261(5120):480-483 (1993).

EXAMINER

Date Considered

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION
DISCLOSURE
STATEMENT**

Atty. Docket No.: 110.01270101

Serial No.: 09/937,076

Applicant(s): McCarthy et al.

Confirmation No.: 4527

Filing Date: September 19, 2001

Group: 1642

Examiner Initials	Document Description
	Nwariaku et al., "Inhibition of Selectin- and Integrin-Mediated Inflammatory Response after Burn Injury" <u>Journal of Surgical Research</u> , <u>63</u> (1):355-358 (1996).
	O'Toole et al., "Regulation of Integrin Affinity States through an NPXY Motif in the β Subunit Cytoplasmic Domain," <u>The Journal of Biological Chemistry</u> , <u>270</u> (15):8553-8558 (1995).
	Parker et al., "New Hydrophilicity Scale Derived from High-Performance Liquid Chromatography Peptide Retention Data: Correlation of Predicted Surface Residues with Antigenicity and X-ray-Derived Accessible Sites," <u>Biochemistry</u> , <u>25</u> (19):5425-5432 (1986).
	Prosper et al., "Mobilization and Homing of Peripheral Blood Progenitors Is Related to Reversible Downregulation of $\alpha 4 \beta 1$ Integrin Expression and Function," <u>The Journal of Clinical Investigation</u> , <u>101</u> (11):2456-2467 (1998).
	Pujades et al., "Defining Extracellular Integrin α -Chain sites That Affect Cell Adhesion and Adhesion Strengthening without Altering Soluble Ligand Binding," <u>Molecular Biology of the Cell</u> , <u>8</u> (12):2647-2657 (1997).
	Radzicka et al., "Comparing the Polarities of the Amino Acids: Side-Chain Distribution Coefficients between the Vapor Phase, Cyclohexane, 1-Octanol, and Neutral Aqueous Solution," <u>Biochemistry</u> , <u>27</u> (5):1664-1670 (1988).
	Ruoslahti, "Integrins," <u>The Journal of Clinical Investigation</u> , <u>87</u> (1):1-5 (1991).
	Scallion et al., "Primary Structure and Functional Activity of a Phosphatidylinositol-Glycan-Specific Phospholipase D," <u>Science</u> , <u>252</u> (5004):446-448 (1991).
	Seki et al., "Quantitative Analysis of Digestion Resistant ACE Inhibitory Dipeptides by Small Intestinal Mucosa," <u>Journal of Japanese Society of Food Science and Technology</u> , <u>43</u> (8):967-969, Japanese language article with English language abstract (1996).
	Springer, "Adhesion Receptors of the Immune System," <u>Nature</u> , <u>346</u> (6283):425-434 (1990).
	Springer, "Folding of the N-terminal, Ligand-binding Region of Integrin α -Subunits into a β -propeller Domain," <u>Proceedings of the National Academy of Sciences USA</u> , <u>94</u> (1):65-72 (1997).

EXAMINER

Date Considered

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION
DISCLOSURE
STATEMENT**

Atty. Docket No.: 110.01270101

Serial No.: 09/937,076

Applicant(s): McCarthy et al.

Confirmation No.: 4527

Filing Date: September 19, 2001

Group: 1642

MAR 19 2002

Examiner
Initial

Document Description

Takada et al., "Identification of a Regulatory Region of Integrin β_1 Subunit Using Activating and Inhibiting Antibodies," The Journal of Biological Chemistry, 268(23):17597-17601 (1993).

Takada et al., "Structural Basis of Integrin-Mediated Signal Transduction," Matrix Biology, 16(4):143-151 (1997).

Tuckwell et al., "A Secondary Structure Model of the Integrin α Subunit N-Terminal Domain Based on Analysis of Multiple Alignments," Cell Adhesion and Communication, 2(5):385-402 (1994).

Wahl et al., "Synthetic Fibronectin Peptides Suppress Arthritis in Rats by Interrupting Leukocyte Adhesion and Recruitment," The Journal of Clinical Investigation, 94(2):655-662 (1994).

Weiss, "Tissue Destruction by Neutrophils," The New England Journal of Medicine, 320(6):365-376 (1989).

Wilke et al., "Human Keratinocytes Adhere to and Spread on Synthetic Peptide FN-C/H-V Derived from Fibronectin," The Journal of Investigative Dermatology, 101(1):43-48 (1993).

Woods et al., "A Synthetic Peptide from the COOH-Terminal Heparin-binding Domain of Fibronectin Promotes Focal Adhesion Formation," Molecular Biology of the Cell, 4(6):605-613 (1993).

Xiong et al., "Crystal Structure of the Extracellular Segment of Integrin $\alpha V\beta 3$," Science, 294(5541):339-45 (2001).

Yanaka et al., "Synthetic Fibronectin Peptides and Ischemic Brain Injury after Transient Middle Cerebral Artery Occlusion in Rats," Journal of Neurosurgery, 85(1):125-130 (1996).

Yanaka et al., "Neuronal Protection from Cerebral Ischemia by Synthetic Fibronectin Peptides to Leukocyte Adhesion Molecules," Journal of Cerebral Blood Flow and Metabolism, 16(6):1120-1125 (1996).

Yanaka et al., "Antagonism of Leukocyte Adherence by Synthetic Fibronectin Peptide V in a Rat Model of Transient Focal Cerebral Ischemia," Neurosurgery, 40(3):557-563 (1997).

EXAMINER

Date Considered

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.